Bispecific antibodies are improving survival and reshaping frontline and relapsed/refractory DLBCL treatment options. Here’s a roundup of the latest key developments.
Want to know the latest news and articles posted on ONC?
Then subscribe to their feed now! You can receive their updates by email, via mobile or on your personal news page on this website.
See what they recently published below.
Website title: Oncologynewscentral.com